TNF and myeloid sarcoma: Similar, an open-label phase I safety trial showed that two rapidly progressive MS patients showed increased MRI activity and immune activation after treatment with infliximab (van Oosten et al., 1996), and during anti-TNF therapy some juvenile RA patients developed MS-like demyelinating lesions (Sicotte and Voskuhl, 2001).